Liver X receptor agonist inhibits HIV-1 replication and prevents HIV-induced reduction of plasma HDL in humanized mouse model of HIV infection

Biochemical and Biophysical Research Communications

Volumn 419, Issue 1, 2012, Pages 95-98

  Dubrovsky, Larisa ^a   Duyne, Rachel Van ^a,b   Senina, Svetlana ^b   Guendel, Irene ^b   Pushkarsky, Tatiana ^a   Sviridov, Dmitri ^c   Kashanchi, Fatah ^b   Bukrinsky, Michael ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Atherosclerosis; HIV 1; Humanized mice; Liver X receptor agonist; Pathogenesis

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; HYDROCARBONS, FLUORINATED; LIPID METABOLISM; LIPOPROTEINS, HDL; MICE; ORPHAN NUCLEAR RECEPTORS; STEM CELL TRANSPLANTATION; SULFONAMIDES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84857651766     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.137     Document Type: Article

References (33)

1. Asztalos B.F., Mujawar Z., Morrow M.P., Grant A., Pushkarsky T., Wanke C., Shannon R., Geyer M., Kirchhoff F., Sviridov D., Fitzgerald M.L., Bukrinsky M., Mansfield K.G. Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux. J. Infect. Dis. 2010, 202:614-623.
2. Crowe S.M., Westhorpe C.L., Mukhamedova N., Jaworowski A., Sviridov D., Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J. Leukoc. Biol. 2010, 87:589-598.
3. Mujawar Z., Rose H., Morrow M.P., Pushkarsky T., Dubrovsky L., Mukhamedova N., Fu Y., Dart A., Orenstein J.M., Bobryshev Y.V., Bukrinsky M., Sviridov D. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS. Biol. 2006, 4:e365.
4. Peet D.J., Janowski B.A., Mangelsdorf D.J. The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 1998, 8:571-575.
5. Repa J.J., Mangelsdorf D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 2000, 16:459-481.
6. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
7. Pelton P.D., Patel M., Demarest K.T. Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr. Top. Med. Chem. 2005, 5:265-282.
8. Rigamonti E., Helin L., Lestavel S., Mutka A.L., Lepore M., Fontaine C., Bouhlel M.A., Bultel S., Fruchart J.C., Ikonen E., Clavey V., Staels B., Chinetti-Gbaguidi G. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ. Res. 2005, 97:682-689.
9. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
10. Beltowski J. Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovasc. Ther. 2008, 26:297-316.
11. Lee J.H., Park S.M., Kim O.S., Lee C.S., Woo J.H., Park S.J., Joe E.H., Jou I. Differential SUMOylation of LXR alpha and LXR beta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes. Mol. Cell 2009, 35:806-817.
12. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
13. Morrow M.P., Grant A., Mujawar Z., Dubrovsky L., Pushkarsky T., Kiselyeva Y., Jennelle L., Mukhamedova N., Remaley A.T., Kashanchi F., Sviridov D., Bukrinsky M. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol. Pharmacol. 2010, 78:215-225.
14. Hanley T.M., Viglianti G.A. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J. Virol. 2011, 85:10834-10850.
15. Rose H., Hoy J., Woolley I., Tchoua U., Bukrinsky M., Dart A., Sviridov D. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008, 199:79-86.
16. Bukrinsky M., Sviridov D. HIV and cardiovascular disease: contribution of HIV-infected macrophages to development of atherosclerosis. PLoS Med. 2007, 4:e43.
17. Van D.R., Cardenas J., Easley R., Wu W., Kehn-Hall K., Klase Z., Mendez S., Zeng C., Chen H., Saifuddin M., Kashanchi F. Effect of transcription peptide inhibitors on HIV-1 replication. Virology 2008, 376:308-322.
18. Van D.R., Pedati C., Guendel I., Carpio L., Kehn-Hall K., Saifuddin M., Kashanchi F. The utilization of humanized mouse models for the study of human retroviral infections. Retrovirology 2009, 6:76.
19. Shultz L.D., Lyons B.L., Burzenski L.M., Gott B., Chen X., Chaleff S., Kotb M., Gillies S.D., King M., Mangada J., Greiner D.L., Handgretinger R. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174:6477-6489.
20. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 2002, 277:34182-34190.
21. Hardy H., Skolnik P.R. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 2004, 24:198-211.
22. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
23. - mice. Proc. Natl. Acad. Sci. USA 2006, 103:15951-15956.
24. - mice. J. Virol. 2009, 83:8254-8258.
25. Doranz B.J., Rucker J., Yi Y., Smyth R.J., Samson M., Peiper S.C., Parmentier M., Collman R.G., Doms R.W. A dual-tropic primary HIV-1 isolate that uses fusin and the beta- chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
26. Cha J.Y., Repa J.J. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 2007, 282:743-751.
27. Rader D.J. Liver X receptor and farnesoid X receptor as therapeutic targets. Am. J. Cardiol. 2007, 100:n15-n19.
28. Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., Feingold K.R. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 1992, 74:1045-1052.
29. Haugaard S.B., Andersen O., Pedersen S.B., Dela F., Fenger M., Richelsen B., Madsbad S., Iversen J. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 2006, 55:175-182.
30. Yokoyama S. Assembly of high-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 2006, 26:20-27.
31. Miao B., Zondlo S., Gibbs S., Cromley D., Hosagrahara V.P., Kirchgessner T.G., Billheimer J., Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 2004, 45:1410-1417.
32. - mice without inducing liver steatosis and hypertriglyceridemia. J. Lipid Res. 2009, 50:312-326.
33. Mangili A., Jacobson D.L., Gerrior J., Polak J.F., Gorbach S.L., Wanke C.A. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin. Infect. Dis. 2007, 44:1368-1374.